| Comprehensive molecular characterization of gastric adenocarcinoma Cancer Genome Atlas Research Network Nature 513 (7517), 202, 2014 | 5435 | 2014 |
| Tumor mutational load predicts survival after immunotherapy across multiple cancer types RM Samstein, CH Lee, AN Shoushtari, MD Hellmann, R Shen, ... Nature genetics 51 (2), 202-206, 2019 | 3401 | 2019 |
| Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients A Zehir, R Benayed, RH Shah, A Syed, S Middha, HR Kim, P Srinivasan, ... Nature medicine 23 (6), 703-713, 2017 | 3143 | 2017 |
| OncoKB: a precision oncology knowledge base D Chakravarty, J Gao, S Phillips, R Kundra, H Zhang, J Wang, ... JCO precision oncology 1, 1-16, 2017 | 2228 | 2017 |
| First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised … YY Janjigian, K Shitara, M Moehler, M Garrido, P Salman, L Shen, ... The Lancet 398 (10294), 27-40, 2021 | 2013 | 2021 |
| HER2 amplification: a potential mechanism of acquired resistance to EGFR inhibition in EGFR-mutant lung cancers that lack the second-site EGFR T790M mutation K Takezawa, V Pirazzoli, ME Arcila, CA Nebhan, X Song, E de Stanchina, ... Cancer discovery 2 (10), 922-933, 2012 | 767 | 2012 |
| CheckMate-032 study: efficacy and safety of nivolumab and nivolumab plus ipilimumab in patients with metastatic esophagogastric cancer YY Janjigian, J Bendell, E Calvo, JW Kim, PA Ascierto, P Sharma, PA Ott, ... Journal of Clinical Oncology 36 (28), 2836-2844, 2018 | 616 | 2018 |
| Gastric adenocarcinoma JA Ajani, J Lee, T Sano, YY Janjigian, D Fan, S Song Nature reviews Disease primers 3 (1), 1-19, 2017 | 576 | 2017 |
| The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer YY Janjigian, A Kawazoe, P Yañez, N Li, S Lonardi, O Kolesnik, ... Nature 600 (7890), 727-730, 2021 | 561 | 2021 |
| Microsatellite instability is associated with the presence of Lynch syndrome pan-cancer A Latham, P Srinivasan, Y Kemel, J Shia, C Bandlamudi, D Mandelker, ... Journal of clinical oncology 37 (4), 286-295, 2019 | 556 | 2019 |
| Prospective genotyping of hepatocellular carcinoma: clinical implications of next-generation sequencing for matching patients to targeted and immune therapies JJ Harding, S Nandakumar, J Armenia, DN Khalil, M Albano, M Ly, J Shia, ... Clinical Cancer Research 25 (7), 2116-2126, 2019 | 508 | 2019 |
| Dual Inhibition of EGFR with Afatinib and Cetuximab in Kinase Inhibitor–Resistant EGFR-Mutant Lung Cancer with and without T790M Mutations YY Janjigian, EF Smit, HJM Groen, L Horn, S Gettinger, DR Camidge, ... Cancer discovery 4 (9), 1036-1045, 2014 | 434 | 2014 |
| Prognosis of metastatic gastric and gastroesophageal junction cancer by HER2 status: a European and USA International collaborative analysis YY Janjigian, D Werner, C Pauligk, K Steinmetz, DP Kelsen, E Jäger, ... Annals of oncology 23 (10), 2656-2662, 2012 | 394 | 2012 |
| Genomic characterization of metastatic patterns from prospective clinical sequencing of 25,000 patients B Nguyen, C Fong, A Luthra, SA Smith, RG DiNatale, S Nandakumar, ... Cell 185 (3), 563-575. e11, 2022 | 387 | 2022 |
| Molecular classification of gastric cancer: a new paradigm MA Shah, R Khanin, L Tang, YY Janjigian, DS Klimstra, H Gerdes, ... Clinical cancer research 17 (9), 2693-2701, 2011 | 366 | 2011 |
| Genetic predictors of response to systemic therapy in esophagogastric cancer YY Janjigian, F Sanchez-Vega, P Jonsson, WK Chatila, JF Hechtman, ... Cancer discovery 8 (1), 49-58, 2018 | 339 | 2018 |
| First-line pembrolizumab and trastuzumab in HER2-positive oesophageal, gastric, or gastro-oesophageal junction cancer: an open-label, single-arm, phase 2 trial YY Janjigian, SB Maron, WK Chatila, B Millang, SS Chavan, C Alterman, ... The Lancet Oncology 21 (6), 821-831, 2020 | 326 | 2020 |
| Nivolumab plus chemotherapy or ipilimumab in gastro-oesophageal cancer K Shitara, JA Ajani, M Moehler, M Garrido, C Gallardo, L Shen, ... Nature 603 (7903), 942-948, 2022 | 304 | 2022 |
| An Emerging Entity: Pancreatic Adenocarcinoma Associated with a Known BRCA Mutation: Clinical Descriptors, Treatment Implications, and Future Directions MA Lowery, DP Kelsen, ZK Stadler, KH Yu, YY Janjigian, E Ludwig, ... The oncologist 16 (10), 1397-1402, 2011 | 286 | 2011 |
| Chemotherapy and COVID-19 outcomes in patients with cancer J Jee, MB Foote, M Lumish, AJ Stonestrom, B Wills, V Narendra, V Avutu, ... Journal of Clinical Oncology 38 (30), 3538-3546, 2020 | 284 | 2020 |